datamatters24/research-document-archive huggingface dataset:
after the fiscal year during which the dis-
tribution is made; 
(iv) 20 percent shall become available 
for obligation during the third fiscal year 
after the fiscal year during which the dis-
tribution is made; and 
(v) 20 percent shall become available 
for obligation during the fourth fiscal year 
after the fiscal year during which the dis-
tribution is made. 
(B) AVAILABILITY
OF
AMOUNTS.—Any 
amounts distributed under paragraph (2) shall 
remain available until expended. 
(6) AUTHORIZED USES.—Amounts distributed 
under paragraph (2) from the Fund shall be used to 
support— 
(A) basic research on the underlying basis 
for disease to better address disease prevention, 
diagnosis, and treatment; 
(B) research that fosters disruptive innova-
tion, such as— 
(i) research on diseases or conditions 
for which treatments exist but are inad-
equate, including chronic and acute pain; 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4124.IH
H4124
kjohnson on DSK79L0C42PROD with BILLS
‘‘(v) an explanation of how the devel-
opment and validation activities support 
the test meeting the applicable standard. 
‘‘(B) A summary of the data and informa-
tion in the application for the in vitro clinical 
test, including— 
‘‘(i) a brief description of any existing 
alternative practices or procedures for di-
agnosing the disease or condition for which 
the in vitro clinical test is intended, as ap-
plicable; 
‘‘(ii) a brief description of the foreign 
and domestic marketing history of the test, 
if any, including a list of all countries in 
which the test has been marketed and a 
list of all countries in which the test has 
been withdrawn from marketing for any 
reason related to the applicable standard 
of the in vitro clinical test, if known by the 
applicant; 
‘‘(iii) a summary of the any studies 
submitted for such test, including a de-
scription of the objective of the study, a 
description of the experimental design of 
the study, a brief description of how the 
VerDate Sep 11 2014 
02:14 Jul 08, 2021
Jkt 019200
PO 00000
Frm 00054
Fmt 6652
Sfmt 6201
E:\BILLS\H4128.IH
H4128
pbinns on DSKJLVW7X2PROD with BILLS
after the date on which the joint resolution is intro-
duced or reintroduced in the House of Representa-
tives under subsection (a). If a committee fails to re-
port the joint resolution within that period, the com-
mittee shall be discharged from further consider-
ation of the joint resolution and the joint resolution 
shall be referred to the appropriate calendar. 
(2) PROCEEDING TO CONSIDERATION.— 
(A) IN GENERAL.—After each committee 
authorized to consider a joint resolution reports 
it to the House of Representatives or has been 
discharged from its consideration, it shall be in 
order, not later than 210 days after the date on 
which the joint resolution is introduced or re-
introduced in the House of Representatives 
under subsection (a), to move to proceed to con-
sider the joint resolution in the House of Rep-
resentatives. 
(B) PROCEDURE.—For a motion to pro-
ceed to consideration of a joint resolution— 
(i) all points of order against the mo-
tion are waived; 
(ii) such a motion shall not be in 
order after the House of Representatives 
VerDate Sep 11 2014 
01:59 Jul 23, 2021
Jkt 019200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H4132.IH
H4132
pbinns on DSKJLVW7X2PROD with BILLS
has disposed of a motion to proceed on the 
joint resolution; 
(iii) the previous question shall be 
considered as ordered on the motion to its 
adoption without intervening motion; 
(iv) the motion shall not be debatable; 
and 
(v) a motion to reconsider the vote by 
which the motion is disposed of shall not 
be in order. 
(3) CONSIDERATION.—If the House of Rep-
resentatives proceeds to consideration of a joint res-
olution— 
(A) the joint resolution shall be considered 
as read; 
(B) all points of order against the joint 
resolution and against its consideration are 
waived; 
(C) the previous question shall be consid-
ered as ordered on the joint resolution to its 
passage without intervening motion except 10 
hours of debate equally divided and controlled 
by the proponent and an opponent; 
(D) an amendment to the joint resolution 
shall not be in order; and 
VerDate Sep 11 2014 
01:59 Jul 23, 2021
Jkt 019200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H4132.IH
H4132
pbinns on DSKJLVW7X2PROD with BILLS
IA 
118TH CONGRESS 
2D SESSION 
H. J. RES. 156 
Providing for congressional disapproval under chapter 8 of title 5, United 
States Code, of the rule submitted by the United States Fish and 
Wildlife Service relating to ‘‘Endangered and Threatened Wildlife and 
Plants; Regulations for Interagency Cooperation’’. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 23, 2024 
Mr. DUARTE (for himself and Mr. NEWHOUSE) submitted the following joint 
resolution; which was referred to the Committee on Natural Resources 
JOINT RESOLUTION 
Providing for congressional disapproval under chapter 8 of 
title 5, United States Code, of the rule submitted by 
the United States Fish and Wildlife Service relating to 
‘‘Endangered and Threatened Wildlife and Plants; Regu-
lations for Interagency Cooperation’’. 
Resolved by the Senate and House of Representatives
of the United States of America in Congress assembled, 
That Congress disapproves the rule submitted by the 
United States Fish and Wildlife Service relating to ‘‘En-
dangered and Threatened Wildlife and Plants; Regulations 
VerDate Sep 11 2014 
04:31 May 24, 2024
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\HJ156.IH
HJ156
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(iv)(I) The mechanism established pursuant to 
clause (i) shall provide for a process for— 
‘‘(aa) a manufacturer or sponsor of a drug or 
biological product to request the Secretary to des-
ignate the drug or biological product as a DISARM 
antimicrobial drug; and 
‘‘(bb) the designation (and removal of such des-
ignation) by the Secretary of drugs and biological 
products as DISARM antimicrobial drugs. 
‘‘(II) A designation of a drug or biological product 
as a DISARM antimicrobial drug may be revoked by the 
Secretary if the Secretary determines that— 
‘‘(aa) the drug or biological product no longer 
meets the requirements for a DISARM antimicrobial 
drug under clause (ii); 
‘‘(bb) the request for such designation con-
tained an untrue statement of material fact; or 
‘‘(cc) clinical or other information that was not 
available to the Secretary at the time such designa-
tion was made shows that— 
‘‘(AA) such drug or biological product is 
unsafe for use or not shown to be safe for use 
for individuals who are entitled to benefits 
under part A; or 
VerDate Sep 11 2014 
23:53 Jul 22, 2021
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4127.IH
H4127
pbinns on DSKJLVW7X2PROD with BILLS
I 
117TH CONGRESS 
1ST SESSION H. R. 4121 
To codify a final rule issued by the Secretary of Health and Human Services 
relating to fraud and abuse and the removal of safe harbor protection 
for certain drug rebates, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 24, 2021 
Mr. ARRINGTON introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce, and in addition to the Committee on 
Ways and Means, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To codify a final rule issued by the Secretary of Health 
and Human Services relating to fraud and abuse and 
the removal of safe harbor protection for certain drug 
rebates, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Anti-Kickbacks, Pro-
tecting Rebates for Our Seniors Act’’ or the ‘‘PRO Seniors 
Act’’. 
VerDate Sep 11 2014 
03:17 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4121.IH
H4121
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. CODIFICATION OF HHS FINAL RULE RELATING TO 
FRAUD AND ABUSE AND REMOVAL OF CER-
TAIN DRUG REBATE SAFE HARBOR PROTEC-
TIONS. 
The final rule entitled ‘‘Fraud and Abuse; Removal 
of Safe Harbor Protection for Rebates Involving Prescrip-
tion Pharmaceuticals and Creation of New Safe Harbor 
Protection for Certain Point-of-Sale Reductions in Price 
on Prescription Pharmaceuticals and Certain Pharmacy 
Benefit Manager Service Fees’’, as published by the De-
partment of Health and Human Services in the Federal 
Register on November 30, 2020 (85 Fed. Reg. 76666), 
shall have the force and effect of law beginning on Janu-
ary 1, 2022. 
Æ 
VerDate Sep 11 2014 
03:17 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H4121.IH
H4121
kjohnson on DSK79L0C42PROD with BILLS
I 
117TH CONGRESS 
1ST SESSION H. R. 4122 
To amend the Higher Education Act of 1965 to provide for interest-free 
deferment on student loans for borrowers serving in a medical or dental 
internship or residency program. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 24, 2021 
Mr. BABIN (for himself and Ms. HOULAHAN) introduced the following bill; 
which was referred to the Committee on Education and Labor 
A BILL 
To amend the Higher Education Act of 1965 to provide 
for interest-free deferment on student loans for bor-
rowers serving in a medical or dental internship or resi-
dency program. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Resident Education 
Deferred Interest Act’’ or the ‘‘REDI Act’’. 
VerDate Sep 11 2014 
03:17 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4122.IH
H4122
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. DEFERMENT DURING A MEDICAL OR DENTAL IN-
TERNSHIP OR RESIDENCY PROGRAM. 
Section 455(f) of the Higher Education Act of 1965 
(20 U.S.C. 1087e(f)) is amended— 
(1) in paragraph (1), in the matter preceding 
subparagraph (A), by striking ‘‘A borrower’’ and in-
serting ‘‘Except as provided in paragraph (6), a bor-
rower’’; 
(2) in paragraph (2)(A)— 
(A) in clause (i), by striking ‘‘or’’ after the 
semicolon; 
(B) by striking the matter following clause 
(ii); 
(C) in clause (ii), by striking the comma at 
the end and inserting ‘‘; or’’; and 
(D) by adding at the end the following: 
‘‘(iii) is serving in a medical or dental 
internship or residency program;’’; and 
(3) by adding at the end the following: 
‘‘(6) SPECIAL RULE FOR CERTAIN IN SCHOOL 
DEFERMENT.—Notwithstanding any other provision 
of this Act, a borrower described in paragraph 
(2)(A)(iii) shall be eligible for a deferment, during 
which periodic installments of principal need not be 
VerDate Sep 11 2014 
03:17 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4122.IH
H4122
kjohnson on DSK79L0C42PROD with BILLS
paid and interest shall not accrue on any loan made 
to the borrower under this part.’’. 
Æ 
VerDate Sep 11 2014 
03:17 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H4122.IH
H4122
kjohnson on DSK79L0C42PROD with BILLS
I 
117TH CONGRESS 
1ST SESSION H. R. 4123 
To codify certain rules related to health reimbursement arrangements and 
other account-based group health plans, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 24, 2021 
Mr. BISHOP of North Carolina (for himself, Mr. WESTERMAN, Mr. BUDD, Mr. 
NORMAN, Mr. BALDERSON, Mr. PERRY, Mr. HICE of Georgia, Mr. 
SMUCKER, Mr. STEUBE, Mr. CAWTHORN, and Ms. HERRELL) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committees on Education and Labor, 
and Ways and Means, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To codify certain rules related to health reimbursement ar-
rangements and other account-based group health plans, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; FINDINGS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Increasing Health Coverage through HRAs Act of 
2021’’. 
(b) FINDINGS.—Congress finds the following: 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4123.IH
H4123
kjohnson on DSK79L0C42PROD with BILLS
(1) Permitting health reimbursement arrange-
ments to be used for the purchase of private insur-
ance will allow more small businesses to offer access 
to quality health insurance coverage to their employ-
ees. 
(2) Permitting health reimbursement arrange-
ments to be used for the purchase of private insur-
ance will increase the number of Americans with 
health insurance coverage by as many as 800,000. 
(3) Permitting health reimbursement arrange-
ments to be used for the purchase of private insur-
ance will significantly increase the number of Ameri-
cans obtaining coverage in the individual market, 
leading to more choice, stability, innovation, and 
lower premiums. 
(4) The administration rule permitting health 
reimbursement arrangements to be used for the pur-
chase of private insurance ensures that those with 
pre-existing conditions will not pay more for cov-
erage by requiring workers within each class of em-
ployment to be offered the same coverage regardless 
of health status. 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4123.IH
H4123
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. CODIFICATION OF HEALTH REIMBURSEMENT AR-
RANGEMENTS AND OTHER ACCOUNT-BASED 
GROUP HEALTH PLANS. 
The final rule (84 FR 28888) published on June 20, 
2019, by the Secretary of the Treasury, the Secretary of 
Labor, and the Secretary of Health and Human Services 
(relating to health reimbursement arrangements and other 
account-based group health plans) shall have the full force 
and effect of law. 
Æ 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H4123.IH
H4123
kjohnson on DSK79L0C42PROD with BILLS
I 
117TH CONGRESS 
1ST SESSION H. R. 4125 
To authorize Inspectors General to continue operations during a lapse in 
appropriations, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 24, 2021 
Mr. CONNOLLY (for himself and Mr. HICE of Georgia) introduced the 
following bill; which was referred to the Committee on Oversight and Reform 
A BILL 
To authorize Inspectors General to continue operations 
during a lapse in appropriations, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Keep the Watchdogs 
Running Act’’. 
SEC. 2. INSPECTOR GENERAL OVERSIGHT DURING LAPSE 
IN APPROPRIATIONS. 
Subsection (g) of section 6 of the Inspector General 
Act of 1978 (5 U.S.C. App.) is amended by adding at the 
end the following new paragraph: 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4125.IH
H4125
kjohnson on DSK79L0C42PROD with BILLS
‘‘(4) Notwithstanding any other provision of law and 
in addition to any other authority, during a lapse in appro-
priations, an Inspector General may incur obligations in 
advance of appropriations— 
‘‘(A) for such amounts as may be necessary and 
at a rate for operations and under the authority and 
conditions as provided in the most recently enacted 
appropriations Acts; and 
‘‘(B) to perform the duties of the Office with 
respect to any program and operation of the estab-
lishment that continues during the lapse in appro-
priations.’’. 
Æ 
VerDate Sep 11 2014 
03:18 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H4125.IH
H4125
kjohnson on DSK79L0C42PROD with BILLS
‘‘(BB) an alternative to such drug or bio-
logical product is an advance that substantially 
improves the diagnosis or treatment of such in-
dividuals. 
‘‘(III) Not later than October 1, 2021, the Secretary 
shall publish in the Federal Register a list of the DISARM 
antimicrobial drugs designated under this subparagraph 
pursuant to the process established under subclause 
(I)(bb). The Secretary shall annually update such list. 
‘‘(v)(I) For purposes of determining additional pay-
ment amounts under clause (i), a manufacturer or sponsor 
of a drug or biological product that submits a request de-
scribed in clause (iv)(I)(aa) shall submit to the Secretary 
information described in section 1927(b)(3)(A)(iii). 
‘‘(II) The penalties for failure to provide timely infor-
mation under clause (i) of subparagraph (C) section 
1927(b)(3) and for providing false information under 
clause (ii) of such subparagraph shall apply to manufac-
turers and sponsors of a drug or biological product under 
this section with respect to information under subclause 
(I) in the same manner as such penalties apply to manu-
facturers under such clauses with respect to information 
under subparagraph (A) of such section. 
‘‘(vi)(I) The mechanism established pursuant to 
clause (i) shall provide that— 
VerDate Sep 11 2014 
23:53 Jul 22, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4127.IH
H4127
pbinns on DSKJLVW7X2PROD with BILLS
(c) DEFINITIONS.—In this section: 
(1) The terms ‘‘elementary school’’ and ‘‘sec-
ondary school’’ have the meanings given to such 
terms in section 8101 of the Elementary and Sec-
ondary Education Act of 1965 (20 U.S.C. 7801). 
(2) The term ‘‘institution of higher education’’ 
has the meaning given to such term in section 101 
of the Higher Education Act of 1965 (20 U.S.C. 
1001). 
(3) The term ‘‘school’’ means a public or pri-
vate kindergarten, a public or private elementary 
school or secondary school, or an institution of high-
er education. 
Æ 
VerDate Sep 11 2014 
02:14 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H4126.IH
H4126
kjohnson on DSK79L0C42PROD with BILLS
119TH CONGRESS 
1ST SESSION 
H. R. 845 
AN ACT 
To require the Secretary of the Interior to reissue regulations 
removing the gray wolf from the list of endangered and 
threatened wildlife under the Endangered Species Act 
of 1973. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
•HJ 156 IH 
for Interagency Cooperation’’ (89 Fed. Reg. 24268 (April 
5, 2024)), and such rule shall have no force or effect. 
Æ 
VerDate Sep 11 2014 
04:31 May 24, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\HJ156.IH
HJ156
kjohnson on DSK7ZCZBW3PROD with $$_JOB
119TH CONGRESS 
1ST SESSION 
H. R. 859 
AN ACT 
To require the disclosure of a camera or recording capability 
in certain internet-connected devices. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
I 
117TH CONGRESS 
1ST SESSION H. R. 4129 
To promote the United States-Greece defense partnership, and for other 
purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 24, 2021 
Mr. DEUTCH (for himself and Mr. BILIRAKIS) introduced the following bill; 
which was referred to the Committee on Foreign Affairs 
A BILL 
To promote the United States-Greece defense partnership, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘U.S.-Greece Defense 
and Interparliamentary Partnership Act of 2021’’. 
SEC. 2. FINDINGS. 
Congress makes the following findings: 
(1) The United States and Greece are strong 
allies in the North Atlantic Treaty Organization 
(NATO) and have deepened their defense relation-
VerDate Sep 11 2014 
02:15 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4129.IH
H4129
kjohnson on DSK79L0C42PROD with BILLS
ship in recent years in response to growing security 
challenges in the Eastern Mediterranean region. 
(2) Greece participates in several NATO mis-
sions, including Operation Sea Guardian in the Med-
iterranean and NATO’s mission in Kosovo. 
(3) The Eastern Mediterranean Security and 
Energy Partnership Act (title II of division J of 
Public Law 116–94), authorized new security assist-
ance for Greece and Cyprus, lifted the United States 
prohibition on arms transfers to Cyprus, and author-
ized the establishment of a United States-Eastern 
Mediterranean Energy Center to facilitate energy co-
operation among the United States, Greece, Israel, 
and Cyprus. 
(4) The United States has demonstrated its 
support for the trilateral partnership of Greece, 
Israel, and Cyprus through joint engagement with 
Cyprus, Greece, Israel, and the United States in the 
‘‘3+1’’ format. 
(5) The United States and Greece have held 
Strategic Dialogue meetings in Athens, Washington 
DC, and virtually, and have committed to hold an 
upcoming Strategic Dialogue session in 2021 in 
Washington, DC. 
VerDate Sep 11 2014 
02:15 Jul 10, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4129.IH
H4129
kjohnson on DSK79L0C42PROD with BILLS
119TH CONGRESS 
1ST SESSION 
H. R. 862 
AN ACT 
To reduce commuting burdens on Transportation Security 
Administration employees, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
(iii) a description of the home and 
community-based services not available 
under the State Medicaid program; 
(iv) a description of the populations 
for which the State is unable to provide 
home and community-based services under 
the State Medicaid program that are pro-
vided under the Medicaid programs of 
other States; and 
(v) a description of barriers to access-
ing home and community-based services 
identified by eligible individuals and fami-
lies of such individuals. 
(C) UTILIZATION.—An assessment of the 
utilization of home and community-based serv-
ices in the State. 
(D) SERVICE DELIVERY STRUCTURES.—A 
description of the service delivery structures for 
providing home and community-based services 
in the State, including with respect to the use 
and models of self-direction, the provision of 
services by agencies, the ownership of service 
provider agencies, the use of managed care 
versus fee-for-service to provide such services, 
and the supports provided for family caregivers. 
VerDate Sep 11 2014 
02:15 Jul 23, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4131.IH
H4131
pbinns on DSKJLVW7X2PROD with BILLS